Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001683168-25-008266
Filing Date
2025-11-12
Accepted
2025-11-12 17:00:13
Documents
3

Document Format Files

Seq Description Document Type Size
1 FORM DEFA14A cns_defa14a.htm DEFA14A 21069
2 GRAPHIC image_060.jpg GRAPHIC 125494
3 GRAPHIC image_061.jpg GRAPHIC 209350
  Complete submission text file 0001683168-25-008266.txt   483393
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39126 | Film No.: 251473983
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)